Freeline Therapeutics Holdings plc Quarterly Income Tax Expense (Benefit) in USD from Q1 2020 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Freeline Therapeutics Holdings plc quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2020 to Q1 2023.
  • Freeline Therapeutics Holdings plc Income Tax Expense (Benefit) for the quarter ending March 31, 2023 was $162K, a 636% increase year-over-year.
  • Freeline Therapeutics Holdings plc annual Income Tax Expense (Benefit) for 2022 was $368K, a 7.6% increase from 2021.
  • Freeline Therapeutics Holdings plc annual Income Tax Expense (Benefit) for 2021 was $342K, a 165% increase from 2020.
  • Freeline Therapeutics Holdings plc annual Income Tax Expense (Benefit) for 2020 was $129K, a 8.51% decline from 2019.
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 $162K +$140K +636% Jan 1, 2023 Mar 31, 2023 6-K 2023-05-30
Q1 2022 $22K +$13K +144% Jan 1, 2022 Mar 31, 2022 6-K 2023-05-30
Q1 2021 $9K -$122K -93.1% Jan 1, 2021 Mar 31, 2021 6-K 2022-05-10
Q1 2020 $131K Jan 1, 2020 Mar 31, 2020 6-K 2021-05-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.